Relmada Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
16.6%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$0.41next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Initial 3-Month NDV-01 Phase 3 Data Release | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly234MTarget: Sufficient to fund operations through 2029
Quarterly Net Loss Quarterly-19.1MTarget: Minimize cash burn during Phase 3 trials
NDV-01 Complete Response (CR) Rate at 12 Months (Phase 2 High-Risk NMIBC) Annually76.0%Target: Maintain high durability in Phase 3 RESCUE program
Watch Items
- NDV-01 Phase 3 RESCUE Program InitiationTrigger: Initiation delay past mid-2026Action: Re-evaluate clinical timeline, operational cash burn, and competitive positioning against approved therapies.
- Sepranolone Phase 2 Trial Initiation in Prader-Willi Syndrome (PWS)Trigger: Initiation delay past mid-2026Action: Assess clinical development strategy and resource allocation for the neurosteroid pipeline.
- Initial 3-Month NDV-01 Phase 3 Data (2L BCG-Unresponsive Cohort)Trigger: Complete Response (CR) rate significantly below Phase 2 levels (94% any-time CR / 80% 12-month CR)Action: Conduct strategic review of the RESCUE program and evaluate alternative registrational pathways.
Research as of 20 Jun 2026